Regeneron's Genetics Center has initiated a large-scale proteomics study analyzing 200,000 blood samples from the Geisinger Health Study to enhance understanding of complex diseases and accelerate drug development. The initiative complements its ongoing UK Biobank Pharma Proteomics Project by incorporating proteomic data alongside genomic sequencing. Utilizing the Olink Explore HT platform, the project targets 5,400 protein markers per sample, aiming to elucidate molecular links between genetics and clinical phenotypes across a multi-generational cohort enriched for diseases such as psoriasis, Alzheimer’s, and type 2 diabetes. This endeavor underscores proteomics' emerging role in bridging genotype and phenotype in precision medicine.